Canine Cell, Per Se Patents (Class 435/350)
  • Patent number: 10982186
    Abstract: The present invention relates to a cell culturing method and kit. More specifically, it relates to a cell culturing method and kit using a support that is exposed to the air. It further relates to a method of culturing cells by allowing them to migrate onto a porous polyimide film.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: April 20, 2021
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Masahiko Hagihara, Motohisa Shimizu, Yukinori Wada
  • Patent number: 9447408
    Abstract: The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells by inhibiting p38 function in the step of somatic cell nuclear reprogramming. The 38 function can be inhibited by bringing an inhibitor selected from the group consisting of (1) a chemical inhibitor of p38 (2) a dominant negative mutant of p38 or a nucleic acid that encodes the same, (3) a nucleic acid selected from the group consisting of siRNAs and shRNAs targeted to p38 and DNAs that encode the same and (4) an inhibitor of p38 pathway into contact with a somatic cell and the like.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: September 20, 2016
    Assignee: Kyoto University
    Inventors: Shinya Yamanaka, Yoshinori Yoshida, Hidaka Yokota
  • Publication number: 20150139953
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 21, 2015
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Publication number: 20150141289
    Abstract: The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Inventors: Kambiz Shekdar, Dennis J. Sawchuk, Jessica C. Langer
  • Publication number: 20150132330
    Abstract: Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.
    Type: Application
    Filed: September 19, 2012
    Publication date: May 14, 2015
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Natalie Pica, Dirk Eggink, Rafael A. Medina-Silva, Rong Hai
  • Publication number: 20150132277
    Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 14, 2015
    Inventors: Paul Schimmel, Xiang-Lei Yang, Bonnie Slike
  • Publication number: 20150132853
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 14, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventor: Karen B. Chapman
  • Publication number: 20150132845
    Abstract: Devices, systems, and methods for continuous cell culture and other reactions are generally described. In some embodiments, chambers (e.g., cell growth chambers) including at least a portion of a wall formed of a flexible member are provided. A retaining structure can be incorporated outside and proximate to the chamber such that when liquid is added to the chamber, the flexible member is consistently and predictably deformed, and a consistent volume of liquid is added. The flexible member can be formed of, in some embodiments, a gas-permeable medium. In some embodiments, reaction chambers can be arranged in a fluidic loop, and a bypass channel can be used to introduce and/or extract fluid from the loop without affecting loop operation.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 14, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: Rajeev Jagga Ram, Kevin Shao-Kwan Lee
  • Publication number: 20150079127
    Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 19, 2015
    Inventors: Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jos Kleuskens, Andreas Walter Claudius Rohwer
  • Publication number: 20150065560
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: March 5, 2015
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
  • Publication number: 20150064148
    Abstract: The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Applicant: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan
  • Publication number: 20150050298
    Abstract: A method for suppressing an immune response is provided. The method involves administration of isolated lymphoid tissue-derived suppressive stromal cells (LSSC) to a subject in need of such treatment in an amount effective to suppress the immune response in the subject. The invention also involves a method to isolate LSSC by digesting lymphoid tissue fragments using a combination of an enzyme mix and agitation and then collecting the LSSC. Pharmaceutical preparations comprising LSSC are also provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 19, 2015
    Inventors: Anne Fletcher, Shannon J. Turley, Biju Parekkadan
  • Publication number: 20150044772
    Abstract: An inactive CRISPR/Cas system-based fusion protein and its applications in gene editing are disclosed. More particularly, chimeric fusion proteins including an inCas fused to a DNA modifying enzyme and methods of using the chimeric fusion proteins in gene editing are disclosed. The methods can be used to induce double-strand breaks and single-strand nicks in target DNAs, to generate gene disruptions, deletions, point mutations, gene replacements, insertions, inversions and other modifications of a genomic DNA within cells and organisms.
    Type: Application
    Filed: August 8, 2014
    Publication date: February 12, 2015
    Inventor: Guojun Zhao
  • Publication number: 20150037292
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Application
    Filed: February 11, 2013
    Publication date: February 5, 2015
    Applicant: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • Publication number: 20150030573
    Abstract: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
    Type: Application
    Filed: October 26, 2013
    Publication date: January 29, 2015
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Johannes H. Fruehauf, Ching J. Li
  • Publication number: 20150017138
    Abstract: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Johannes H. Fruehauf, Chiang J. Li
  • Publication number: 20150010593
    Abstract: The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 8, 2015
    Inventors: Marciela Degrace, Nir Hacohen, Sagi Shapira, Liguo Wu
  • Publication number: 20150005369
    Abstract: Disclosed are methods of gene delivery using capsid-modified recombinant adeno-associated viral (rAAV) vectors. Exemplary methods are provided employing vectors that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are methods employing the rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 1, 2015
    Inventors: Nicholas Muzyczka, Shaun R. Opie, Kenneth H. Warrington
  • Publication number: 20140377803
    Abstract: The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell.
    Type: Application
    Filed: May 14, 2012
    Publication date: December 25, 2014
    Applicant: PROBIOGEN AG
    Inventors: Volker Sandig, Karsten Winkler, Henning Von Horsten, Thomas Rose
  • Publication number: 20140377296
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Application
    Filed: April 17, 2014
    Publication date: December 25, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 8912161
    Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: December 16, 2014
    Assignee: Regulus Therapeutics, Inc.
    Inventor: Balkrishen Bhat
  • Patent number: 8911776
    Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: December 16, 2014
    Inventor: Claresa Levetan
  • Patent number: 8900860
    Abstract: The present invention relates to a novel method for expanding mesenchymal stem cells (MSCs) in low-density and hypoxic condition as compared to normal air conditions traditionally used in cell culture. The present method provides rapid and efficient expansion of human MSCs without losing cellular proliferation and stem cell properties, including increase in proliferation, decrease in senescence, and increase in differentiation potential both in vitro and in vivo. The expanded MSCs by the present method may maintain normal karyotyping, and will not form tumor when transplanted into mammal.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: December 2, 2014
    Assignee: National Yang-Ming University
    Inventor: Shih-Chieh Hung
  • Publication number: 20140328875
    Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 6, 2014
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
  • Publication number: 20140323401
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 30, 2014
    Applicant: Araim Pharmaceuticals, Inc.
    Inventors: Anthony CERAMI, Michael BRINES, Thomas COLEMAN
  • Publication number: 20140322182
    Abstract: The present invention relates to canine amniotic membrane-derived multipotent stem cells (cAM-MSCs) and preparation method thereof. More particularly, the present invention relates to canine amniotic membrane-derived multipotent stem cells, which show negative immunological properties on human markers CD3, CD11c, CD28, CD34, CD38, CD41a, CD45, and CD62L and positive immunological properties on human markers CD90 and CD105, and have the ability to be maintained in an undifferentiated state for 20 passages or more and the ability to be differentiated into fat, bones, nerves, cartilage, etc.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 30, 2014
    Inventors: Kyung Sun Kang, Min Soo Seo, Sang Bum Park
  • Publication number: 20140322812
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: April 24, 2014
    Publication date: October 30, 2014
    Applicant: Intrexon Corporation
    Inventors: Subba Reddy PALLI, Mohan Basavaraju KUMAR
  • Publication number: 20140315804
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 23, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Publication number: 20140308704
    Abstract: The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus.
    Type: Application
    Filed: November 22, 2012
    Publication date: October 16, 2014
    Inventors: Seung Shin Yu, Chang-Wan Joo, Jin-A Chae, Yeon Suk Cha
  • Publication number: 20140308247
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals. The vector may be provided to treat or prevent disease.
    Type: Application
    Filed: March 2, 2012
    Publication date: October 16, 2014
    Applicant: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Brandon Cuthbertson, Charles C. Reed, Sunil Chada, William E. Fogler, Fayas Khazi
  • Patent number: 8858928
    Abstract: The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: October 14, 2014
    Assignee: bluebird bio, Inc.
    Inventors: Maria Joann Denaro, Mitchell Howard Finer, Gabor Veres, Julian Down
  • Publication number: 20140302077
    Abstract: Provided are live attenuated influenza A and B viruses as well as a composition, influenza A and B genes, a vector with a respective gene, a host cell comprising such vector, a method for preparing a live attenuated influenza A or B virus and a use of the influenza viruses as a vaccine. An influenza A virus contains a NP-gene, which includes a silent mutation at one or more positions selected from nucleotide 1467, nucleotide 1473, nucleotide 1500, nucleotide 1503, nucleotide 1512, nucleotide 1515, nucleotide 1518, nucleotide 1521, and nucleotide 1524 of SEQ ID No: 1. A PA gene includes a silent mutation at one or more positions corresponding to a position selected from nucleotides 2100 and 2103 of SEQ ID No: 3.
    Type: Application
    Filed: August 28, 2012
    Publication date: October 9, 2014
    Applicant: Westfaelische Wilhelms-Universitaet Munester
    Inventors: Darisuren Anhlan, Christoph Scholtissek, Stephan Ludwig
  • Patent number: 8846373
    Abstract: The present invention relates to new methods to promote sialylation of glycoconjugates, including recombinant glycoproteins, in glycoconjugate production systems. The invention relates to methods to promote efficient glycoconjugate sialylation in recombinant expression systems, by providing simpler and more economical ways to produce large intracellular pools of sialic acid precursors. The invention is directed to nucleic acids, vectors, and cells harboring vectors comprising nucleic acids encoding enzymes involved in the synthesis of sialic acid precursors, and cells harboring these nucleic acids in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins in bacterial, fungal, plant, and animal cell expression systems.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: September 30, 2014
    Assignee: The University of Wyoming
    Inventors: Christoph Geisler, Donald Jarvis
  • Publication number: 20140287512
    Abstract: A method of cultivating cells in a bag is disclosed, which comprises the steps of: a) providing a sterile flexible bag comprising a filter material which is attached to a wall of the culture bag, wherein the filter material delimits a chamber inside the bag and wherein the chamber is fluidically connected to a first port in a wall of the bag, b) providing agitation means for the bag, c) introducing cell culture medium, microcarriers and cells to the bag, d) cultivating cells in the bag with agitation provided by the agitation means, allowing formation of a suspension of microcarriers with immobilized cells and supplying at least one gas via a second port (not shown) in a wall of the bag, e) removing cell debris and/or free cells together with liquid from said suspension of microcarriers through the filter material and the first port.
    Type: Application
    Filed: May 15, 2012
    Publication date: September 25, 2014
    Inventors: Christian Kaisermayer, Eva Lindskog
  • Publication number: 20140273206
    Abstract: The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Genzyme Corporation
    Inventors: Xiaoxia JIN, Haodi DONG, Claudia BUSER
  • Publication number: 20140273097
    Abstract: Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: Sangamo BioSciences, Inc.
    Inventors: Trevor Collingwood, Gregory J. Cost
  • Publication number: 20140235535
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
    Type: Application
    Filed: July 3, 2012
    Publication date: August 21, 2014
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
  • Publication number: 20140227248
    Abstract: Methods and cell lines for overexpressing functional gamma-carboxylated proteins are disclosed.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 14, 2014
    Inventor: Reidar Wallin
  • Publication number: 20140212928
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Application
    Filed: March 6, 2014
    Publication date: July 31, 2014
    Applicant: Sangamo BioSciences, Inc.
    Inventor: Jianbin Wang
  • Publication number: 20140208457
    Abstract: The present invention is concerned with nuclease fusion proteins and various uses thereof. Specifically, it relates to a polynucleotide encoding a polypeptide comprising (i) a first module comprising at least a first DNA binding domain derived from a homing endonuclease, (ii) a linker, and (iii) a second module comprising at least a second DNA binding domain and a cleavage domain derived from a restriction endonuclease, wherein said polypeptide functionally interacts only with DNA comprising a DNA recognition site for the first DNA binding domain and a DNA recognition site for the second DNA binding domain, and wherein said cleavage domain cleaves DNA within a specific DNA cleavage site upon binding of the polypeptide. Further contemplated are a vector and a non-human transgenic organism comprising said polynucleotide as well as a polypeptide encoded by the polynucleotide of the invention.
    Type: Application
    Filed: June 8, 2012
    Publication date: July 24, 2014
    Applicant: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Ines Fonfara, Wolfgang Wende, Alfred Pingoud
  • Publication number: 20140189895
    Abstract: The present invention provides a method of artificially repressing gene expression, which is simpler to design than conventional methods (the RNAi, ribozyme and antisense methods) and which allows for easier confirmation of the effect. A method of inhibiting the translation reaction of a target gene, comprising cutting out a part of the poly(A) tail and/or 3?-terminal sequence of the target mRNA is provided.
    Type: Application
    Filed: July 17, 2012
    Publication date: July 3, 2014
    Applicants: YOSHINDO INC., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Tadashi Wada, Kei Takeda, Hiroshi Handa
  • Patent number: 8765142
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: July 1, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Publication number: 20140170746
    Abstract: Provided is a method of dedifferentiating somatic cells using embryonic stem cell-derived microvesicles. Particularly, a method of preparing induced pluripotent stem cells by treating a composition including embryonic stem cell-derived microvesicles to the somatic cells. According to the method of preparing induced pluripotent stem cells, the dedifferentiation of the somatic cells may be efficiently performed without side effects using the embryonic stem cell-derived microvesicles, and moreover, the method is expected to be very useful in developing a cell therapy product having immunocompatibilities by individuals.
    Type: Application
    Filed: April 19, 2012
    Publication date: June 19, 2014
    Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Jae-Sung Park, Yong Song Gho, Yoon Keun Kim, Jun Ho Kim, Su Chul Jang, Namwoo Yi, Dayeong Jeong, Eun-Jeong Choi
  • Patent number: 8753882
    Abstract: Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: June 17, 2014
    Assignee: VetGel Technologies
    Inventor: Richard Gold
  • Patent number: 8748174
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: June 10, 2014
    Assignee: MedImmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • Publication number: 20140147458
    Abstract: The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome DNA of VZV MAV/06 strain isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MAV/06 strain and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient.
    Type: Application
    Filed: February 24, 2012
    Publication date: May 29, 2014
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Geun Hee Kim, Shi Nae Kwon, Chan Hee Lee, Yeop Yoon
  • Publication number: 20140147453
    Abstract: The present invention relates to a fusion peptide comprising dhFas-1 domain and MMP substrate and use thereof. More specifically, the present invention relates to a fusion peptide, comprising a) a dhFas-1 domain which is the fourth fas-1 domain of ?ig-h3 lacking H1 and H2 regions; b) a MMP (Matrix metalloproteinase) substrate; and c) a peptide comprising RGD motif and an use thereof for preventing and treating inflammatory disease. The fusion peptide of the present invention inhibits expension of rheumatoid arthritis by adhesion and migration of sinoviocytes and may be used for preventing or treating inflammatory disease by inhibiting infiltration of immune cells.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 29, 2014
    Applicant: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Young Mo Kang, In San Kim, Jin Hee Kang, Keum Hee Sa
  • Patent number: 8728808
    Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: May 20, 2014
    Assignee: Intrexon Corporation
    Inventors: Tarlochan Singh Dhadialla, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, Jr., Mohan Philip
  • Publication number: 20140134740
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 15, 2014
    Applicant: Sangamo BioSciences, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Publication number: 20140134723
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 15, 2014
    Applicant: Sangamo BioSciences, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang